Blog

BenevolentAI wins Innovation Award at 2020 Scrip Awards

BenevolentAI has been selected by an eminent panel of global industry executives as the winner of the Innovation Award at the prestigious 2020 Scrip Awards.

The Innovation Award acknowledges and celebrates ‘Outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines’. This Award follows a momentous year for BenevolentAI and is a testament to our COVID-19 research, the unrivalled strength of our Knowledge Graph and AI models, and the early success of our collaboration with AstraZeneca. 

Our COVID-19 research began in late January and advanced from hypothesis to FDA approval in nine months. Our team identified baricitinib as a potential treatment for COVID-19 in a time frame that would have been impossible to replicate without our sophisticated biomedical knowledge graph and artificial intelligence. In October, clinical data from the NIAID ACTT-2 trial validated our initial hypothesis, and baricitinib was subsequently given emergency approval by the FDA in November.  

This year, our platform also excelled in a collaboration environment: in April 2020, eight months into our partnership with AstraZeneca, we delivered the first output of hypotheses for CKD. Our two teams quickly became one, working closely together to generate a knowledge graph enhanced on CKD and applied AI and ML models to generate a set of targets predicted to be most useful in treating CKD. 

The application of artificial intelligence to drug discovery is unrivalled in its complexity, and we are honoured to have our pioneering work in this field recognised at the Scrip Awards. This year demonstrated the power, scalability and adaptability of our AI-augmented end-to-end drug discovery and development approach. Next year, and for years to come, we will continue our mission to unite human and artificial intelligence to translate data into life-changing medicines which help patients live healthier, happier lives.


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021